Microsoft, Nvidia, and Meta Platforms all look like great values. Taiwan Semiconductor and Broadcom are experiencing massive growth due to the demand for AI chips.
Source: https://www.fool.com/investing/2026/03/12/the-best-stocks-to…
Eli Lilly has outstanding growth prospects thanks to its leadership in its core therapeutic area. AbbVie’s immunosuppressant portfolio helps it to produce steady revenue and profits.
Elevated Chinese exports lift shares for Alibaba, Temu, and Baidu.
International equities experienced a prolonged period of under-performance (2009-2024), challenging investor conviction in global diversification. 2025 witnessed a surge from rock-bottom valuation, leading IDV to breach a 17-year trading range. Strong momentum, and continuing under-investment may signal a ‘1982 moment.’ Reassessing portfolio allocations to international markets may be warranted as relative value and mean reversion dynamics come into focus.
